Elanco Animal Health Inc. will invest US$130 million to renovate its manufacturing facility in Elwood, Kansas, Gov. Laura Kelly announced on August 20.
The expansion in Doniphan County is expected to create approximately 70 new jobs over the next two years.
Elanco’s Elwood site manufactures and ships its canine parvovirus monoclonal antibody and will be the flagship location for Elanco’s future monoclonal antibody manufacturing. The expansion will add the needed capacity to support Elanco’s growth in monoclonal antibody innovation.
“Expanding the capabilities at our Elwood manufacturing site is a critical step toward executing the most exciting pipeline in Elanco’s 70-year history,” Elanco Manufacturing and Quality Executive Vice President Grace McArdle said.
This project will help enhance the local economy through increased tax revenue and serve as a stable long-term employer in Elwood. The company will be better positioned to optimally serve customer demands with improved project development and commercialization lead times.
Design-build firm Burns & McDonnell, headquartered in Kansas City, Missouri, is leading the expansion project as the primary provider of integrated design and construction services.
Elanco said in December 2020 it would establish consolidated headquarters in downtown Indianapolis. Plans include a 45-acre former industrial site located in the southwest corner of downtown Indianapolis on the White River, with a restricted option for an additional 20 acres.
